Pathstone Holdings LLC Boosts Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Pathstone Holdings LLC lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 18.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 27,022 shares of the medical equipment provider’s stock after purchasing an additional 4,294 shares during the quarter. Pathstone Holdings LLC’s holdings in Lantheus were worth $2,966,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Quest Partners LLC lifted its holdings in shares of Lantheus by 27,685.7% during the 3rd quarter. Quest Partners LLC now owns 1,945 shares of the medical equipment provider’s stock worth $213,000 after acquiring an additional 1,938 shares during the last quarter. Swiss National Bank raised its position in Lantheus by 0.4% during the third quarter. Swiss National Bank now owns 135,354 shares of the medical equipment provider’s stock valued at $14,855,000 after purchasing an additional 500 shares in the last quarter. RiverPark Advisors LLC bought a new stake in Lantheus during the third quarter worth about $74,000. Natixis Advisors LLC boosted its holdings in shares of Lantheus by 8.2% in the 3rd quarter. Natixis Advisors LLC now owns 46,445 shares of the medical equipment provider’s stock worth $5,097,000 after purchasing an additional 3,516 shares in the last quarter. Finally, CIBC Asset Management Inc bought a new position in shares of Lantheus during the 3rd quarter valued at about $222,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on LNTH. Truist Financial reaffirmed a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities reduced their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, Redburn Atlantic started coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Stock Up 3.7 %

NASDAQ:LNTH opened at $90.52 on Monday. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The stock has a market cap of $6.29 billion, a P/E ratio of 15.06 and a beta of 0.51. The firm’s fifty day simple moving average is $103.13 and its 200 day simple moving average is $96.93.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.